| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| CVD-1301.V01 | hV-01; CVD-1301.V01; V 01 | Phase 2 Clinical | Hangzhou Converd Co Ltd | Pancreatic Neoplasms; Sarcoma 180; Solid tumours; Uterine Cervical Neoplasms | Details |
| IL-21 mab (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Immune System Diseases | Details | |
| triple anti-CD19 CAR T-cell therapy/PD-1 checkpoint inhibitor/IL-21 receptor agonist (CD (Suzhou) Biopharma/Chinese People's Liberation Army General Hospital/Chinese academy of sciences) | Phase 1 Clinical | Chinese Academy Of Sciences | Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD-001 | CD-001 | Phase 1 Clinical | CD (Suzhou) Biopharma Co Ltd | Head and Neck Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Solid tumours | Details |